Literature DB >> 9458207

Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument.

A Silman1, A Akesson, J Newman, H Henriksson, G Sandquist, M Nihill, S Palfrey, R Lomas, F Wollheim, C Black.   

Abstract

OBJECTIVE: To develop a simple assessment of functional ability in patients with scleroderma and to examine its reliability both as a patient self-administered instrument and when administered by a trained observer.
METHODS: An 11 item, 4 grade, functional assessment questionnaire was developed after extensive consultation with patients, physiotherapists (PT), and occupational therapists (OT) with the aim of including all functional areas of relevance. The instrument was self-administered by patients after an interval of 7 days. In the interval, the patients were assessed using the same instrument by direct observation from both a PT and an OT. Forty-seven patients with scleroderma, of varying severity, were recruited from 2 centers. Results were similar for both centers and data were pooled for analysis.
RESULTS: Agreement between the patients' first and 2nd assessment was good for all questions (estimated kappas 0.69 to 0.94) with no evidence of an order effect. Agreement was also good between therapists (estimated kappas 0.47 to 0.81). There was poor agreement between patients and therapists, with patients rating their disability substantially higher compared to the standardized therapist assessment.
CONCLUSION: This assessment schedule has high face and content validity and has excellent reliability both between trained therapists and within patients over a short time period. Its administration either as a self-report or by a therapist depends, in part, on the type of investigation undertaken.

Entities:  

Mesh:

Year:  1998        PMID: 9458207

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

Review 1.  Combination therapies for systemic sclerosis.

Authors:  C P Denton; C M Black
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

3.  Cross-cultural adaptation and validation of the Brazilian version of the Scleroderma Health Assessment Questionnaire (SHAQ).

Authors:  Luiza F Rocha; Roberta G Marangoni; Percival D Sampaio-Barros; Mauricio Levy-Neto; Natalino H Yoshinari; Eloisa Bonfa; Virginia Steen; Sergio C Kowalski
Journal:  Clin Rheumatol       Date:  2013-08-22       Impact factor: 2.980

4.  Evaluation of a mail-delivered, print-format, self-management program for persons with systemic sclerosis.

Authors:  Janet L Poole; Betty Skipper; Cindy Mendelson
Journal:  Clin Rheumatol       Date:  2013-05-09       Impact factor: 2.980

Review 5.  My approach to the treatment of scleroderma.

Authors:  Ami A Shah; Fredrick M Wigley
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

6.  The scleroderma Assessment Questionnaire (SAQ). A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis.

Authors:  P Ostojić; N Damjanov
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

7.  Drug compliance in patients with systemic scleroderma.

Authors:  Lucie Hromadkova; Tomas Soukup; Eva Cermakova; Jiri Vlcek
Journal:  Clin Rheumatol       Date:  2012-08-09       Impact factor: 2.980

8.  Factors related to self-efficacy in persons with scleroderma.

Authors:  Una Buck; Janet Poole; Cindy Mendelson
Journal:  Musculoskeletal Care       Date:  2010-12

Review 9.  Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis.

Authors:  Dinesh Khanna; Ron D Hays; Daniel E Furst
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

Review 10.  Outcome measures in systemic sclerosis: an update on instruments and current research.

Authors:  Dinesh Khanna; Peter A Merkel
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.